Brand Intelligence Graphcompany
Company Overview
About Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Business Model & Competitive Advantage
Pfizer's core commercial portfolio extends across oncology, rare disease, internal medicine, and vaccines. Eliquis (apixaban, co-promoted with Bristol-Myers Squibb) remains the world's best-selling anticoagulant; Ibrance leads in CDK4/6 inhibitor breast cancer therapy; Vyndaqel/Vyndamax dominates the ATTR-CM (transthyretin cardiomyopathy) market where it has achieved blockbuster status. The Prevnar pneumococcal vaccine franchise and Nimenrix meningococcal vaccines anchor a diversified global vaccine portfolio. Pfizer's "Fit-to-Win" restructuring program targets $4 billion in annual cost savings by 2025, realigning R&D investments toward the highest-value pipeline opportunities post-Seagen integration.
Competitive Landscape 2025–2026
In 2025-2026, Pfizer confronts significant patent cliff risks: Eliquis faces generic competition beginning in 2026-2028, representing roughly $7 billion in annual U.S. revenues at risk. The Seagen ADC platform is the primary offense against this cliff, with Padcev already generating $1 billion-plus in annual revenues for metastatic urothelial cancer. Competitive pressures come from AstraZeneca (Enhertu in ADCs), Eli Lilly (oncology expansion), and Merck (Keytruda franchise). Activist investor Starboard Value took a stake in late 2024 and has pressed for more aggressive cost cuts and strategic review. Pfizer's GLP-1 obesity drug danuglipron failed Phase 2 trials in 2023, leaving the company without a direct entry in the fast-growing obesity therapeutics market dominated by Eli Lilly and Novo Nordisk.
The Pfizer Story
Founders
Recent Activity
View all →A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals Substudy A Supplemental CSR – Final Phase 1 Analysis zhoum55 Tue, 09/29/2026 - 03:47 PF-07911145 (VZV modRNA Vaccine) PF-07911145 (VZV modRNA Vaccine) PHASE I Wed, 01/25/2023 - 12:00 Fri, 09/19/2025 - 12:00 NCT05703607 N https://clinicaltrials.gov/study/NCT05703607?term=NCT05703607&viewType=Card&rank=1 C5031001 Substudy A
Long-Term Follow-Up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study zhoum55 Mon, 09/28/2026 - 05:09 PF-06939926 (fordadistrogene movaparvovec) PF-06939926 (fordadistrogene movaparvovec) PHASE III Mon, 03/13/2023 - 12:00 Wed, 09/24/2025 - 12:00 NCT05689164 C3391011 Public Disclosure Synopsis.pdf (140.42 KB) N https://clinicaltrials.gov/study/NCT05689164?term=C3391011&viewType=Card&rank=1 C3391011
Final Report - India Cohort Analysis: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine Given in a Series of 3 Infant Doses and 1 Toddler Dose in Infants in India and Taiwan lul46 Tue, 09/22/2026 - 03:10 Prevnar 20®/Prevenar 20® 20-Valent Pneumococcal Conjugate Vaccine (20vPnC), Compound Number: PF-06482077 PHASE III Fri, 09/16/2022 - 12:00 Sat, 09/20/2025 - 12:00 NCT05512819 B7471024 Public Disclosure Synopsis merged cohorts.pdf (2.39 MB) N https://clinicaltrials.gov/study/NCT05512819?term=B7471024&viewType=Card&rank=1 B7471024
A Phase 1/2 Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Varicella Zoster Virus in Healthy Individuals Substudy A Supplemental CSR – Final Phase 1 Analysis lul46 Mon, 09/21/2026 - 03:08 N/A PF-07911145 (VZV modRNA Vaccine) PHASE I Wed, 01/25/2023 - 12:00 Fri, 09/19/2025 - 12:00 NCT05703607 N https://clinicaltrials.gov/study/NCT05703607?term=C5031001%20Substudy%20A&viewType=Card&rank=1 C5031001 Substudy A
TwoStep Therapeutics riverh29 Mon, 09/14/2026 - 09:01 Active Portfolio Companies TwoStep Therapeutics is a biotechnology company developing a pipeline built around a versatile targeting peptide that selectively binds multiple tumor-associated integrins—a unique feature that enables the delivery of diverse payloads across a wide range of solid tumor types. The company leverages this technology to develop targeted cancer therapies for cytotoxic drug delivery and radioligand therapy. San Carlos, California https://twosteptx.com/
Vaccine Company riverh29 Wed, 08/19/2026 - 12:47 Former Portfolio Companies Advancing novel vaccines using proprietary in vitro nanoparticle technologies. Acquired by Eli Lilly & Co. 2026 San Francisco, CA
Oblenio Bio riverh29 Thu, 08/13/2026 - 13:00 Active Portfolio Companies Oblenio Bio is a clinical-stage company pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through its LBL-051 T cell engager. Specifically engineered for autoimmune patients, this tri-specific unites validated targets BCMA, CD19 and CD3 to safely and completely deplete B cells and plasma cells to achieve long-term drug-free remission. The company is singularly focused on LBL-051’s innovative clinical development program to rapidly establish it as a life-changing treatment for the vast number of patients who endure severe autoimmune disease without relief. Lexington, MA visit www.obleniobio.com
An Interventional, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Chinese Participants zhoum55 Wed, 08/12/2026 - 22:42 Nurtec® Rimegepant (PF-07899801, BHV-3000) PHASE III Mon, 05/15/2023 - 12:00 Wed, 12/10/2025 - 12:00 NCT05810038 C4951019 Public Disclosure Synopsis.pdf (137.13 KB) N https://clinicaltrials.gov/study/NCT05810038?term=C4951019&viewType=Card&rank=1 BHV3000-319 (C4951019)
Quarterly Report filed 2026-08-04
Material Event filed 2026-08-04
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS secchiarolim Wed, 07/15/2026 - 14:08 PF-07926307 (Combination COVID-19 and Influenza modRNA Vaccine) PHASE I/II Mon, 11/11/2024 - 12:00 Tue, 07/15/2025 - 12:00 NCT06683352 C5261023 Public Disclosure Synopsis.pdf (102.04 KB) N https://clinicaltrials.gov/study/NCT06683352?term=C5261023&viewType=Table&rank=1 C5261023
Company Timeline
Major milestones in Pfizer's journey
Leadership Team
Meet the leaders behind Pfizer
Dr. Albert Bourla
Albert Bourla is a Greek-American veterinarian and businessman who became CEO of Pfizer in January 2019 and Chairman in February 2019. During his 30+ years at Pfizer, he held senior management positions across five countries and established Pfizer's Purpose Blueprint with core values of Courage, Excellence, Equity, and Joy to create a culture where science and people thrive.
David M. Denton
Dave Denton joined Pfizer as CFO and Executive Vice President effective May 2, 2022, providing strategic global financial leadership as a member of Pfizer's Executive Leadership Team. He oversees all financial operations and strategy for the company.
Dr. Chris Boshoff
Chris Boshoff, M.D., PhD, was appointed Chief Scientific Officer and President of Research & Development effective January 1, 2025, following a comprehensive selection process. Previously Chief Oncology Research and Development Officer, he leads Pfizer's global R&D efforts and scientific strategy.
Aamir Malik
Aamir Malik is Executive Vice President and Chief U.S. Commercial Officer, leading the U.S. Commercial business including Primary and Specialty Care Commercial and Medical Affairs, Oncology Commercial, Global Access and Value, and Global Chief Marketing Office organizations as a member of the Executive Leadership Team.
Dr. Andrew Baum
Andrew Baum, M.D., joined Pfizer as Chief Strategy and Innovation Officer and Executive Vice President, reporting to CEO Dr. Albert Bourla. He is a member of Pfizer's Executive Leadership Team responsible for corporate strategy and innovation initiatives.
Key Differentiators
Market Leader
Pfizer is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $63.6B in revenue, Pfizer operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Compare Pfizer with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Pfizer? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Pfizer Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Pfizer vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →